Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + gemcitabine + liposomal irinotecan as first-line therapy in advanced biliary tract cancer
ChiCTR2600119377Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Objective Response Rate, Overall Survival and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600119377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119377.